✦ LIBER ✦

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

✍ Scribed by Dent, Rebecca A; Lindeman, Geoffrey J; Clemons, Mark; Wildiers, Hans; Chan, Arlene; McCarthy, Nicole J; Singer, Christian F; Lowe, Elizabeth S; Watkins, Claire L; Carmichael, James

Book ID: 121611284
Publisher: BioMed Central
Year: 2013
Tongue: English
Weight: 207 KB
Volume: 15
Category: Article
ISSN: 1465-5411
DOI: 10.1186/bcr3484

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II trial of oral UFT/Leucovorin

Phase I/II trial of oral UFT/Leucovorin (LV) and paclitaxel (P) in the second line treatment of patients (PTS) with metastatic breast cancer (MBC)

✍ Klaassen, U.; Lang, S.; Borquez, D.; Oberhoff, C.; Benner, S.; Harstrick, A.; Se 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 322 KB

The efficacy and safety of gemcitabine p

The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype

✍ Kenjiro Aogi; Masayuki Yoshida; Yoshiaki Sagara; Shunji Kamigaki; Minoru Okazaki 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 311 KB

A Phase II Trial of Gemcitabine/Carbopla

A Phase II Trial of Gemcitabine/Carboplatin with or Without Trastuzumab in the First-Line Treatment of Patients with Metastatic Breast Cancer

✍ Denise A. Yardley; Howard A. Burris III; Lisa Simons; David R. Spigel; F. Anthon 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 117 KB

Phase II Trial of Saracatinib (AZD0530),

Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer

✍ Ayca Gucalp; Joseph A. Sparano; James Caravelli; Jean Santamauro; Sujata Patil; 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 477 KB

Safety results from a phase III study (T

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

✍ I. Lang; M.J. Inbar; Z. Kahán; R. Greil; S. Beslija; S.M. Stemmer; B. Kaufman; Z 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 302 KB

Phase I study of an all-oral combination

Phase I study of an all-oral combination of vinorelbine (VRL) and cyclophosphamide (Ctx) as second line treatment in patients with metastatic breast cancer (MBC)

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 124 KB